Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 10/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.54 |
| ▸ | RELA | Q04206 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10547490 | 0.88 | HDAC1 (0.48) | MRGPRX4TP53PKMNFKB1NFKB2 | |
| SCHEMBL916101 | 0.88 | MRGPRX4 (0.54) | MRGPRX4TP53PKMNFKB1NFKB2 | |
| SCHEMBL8669463 | 0.88 | HDAC1 (0.50) | MRGPRX4TP53PKMNFKB1NFKB2 | |
| SCHEMBL9454035 | 0.85 | CYP4F2 (0.58) | PKMSMN1; SMN2HDAC1RAB9AKMT2A | |
| SCHEMBL27740956 | 0.85 | MRGPRX4 (0.51) | MRGPRX4TP53PKMNFKB1NFKB2 | |
| SCHEMBL498351 | 0.85 | LOXL2 (0.57) | MRGPRX4SMN1; SMN2FOLH1HDAC1RAB9A | |
| SCHEMBL914194 | 0.84 | MAPT (0.43) | MRGPRX4TP53PKMNFKB1NFKB2 | |
| SCHEMBL3390402 | 0.84 | CCNT1 (0.46) | HDAC1 | |
| SCHEMBL23684777 | 0.82 | SLC7A5 (0.53) | MRGPRX4TP53PKMNFKB1NFKB2 | |
| SCHEMBL14003823 | 0.82 | HDAC1 (0.46) | MRGPRX4TP53PKMNFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250298333-A1 | POLYESTER RESIN COMPOSITION, ELECTROSTATIC CHARGE IMAGE DEVELOPING TONER, DEVELOPER, AND IMAGE FORMING METHOD | Konica Minolta, Inc. (JP) | 2025-09-25 | — | — | US | disclosed |
| US-11986471-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | USHER III INITIATIVE, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | USHER III INITIATIVE, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11077101-B1 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| WO-2016201266-A1 | METHODS OF TREATING OR PREVENTING A PROTEOPATHY | USHER III INITIATIVE, INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| CN-102471366-B | 17-hydroxy-17-pentafluoroethylestra-4, 9(10) -diene 11-benzylidene derivatives, process for preparing them and their use for treating diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-16 | — | — | CN | disclosed |
| US-9156877-B2 | 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzylidene derivatives, methods for the production thereof and use thereof for treating diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-10-13 | — | — | US | disclosed |
| EP-2456782-B1 | 17-HYDROXY-17-PENTAFLUORETHYL-ESTRA-4,9(10)-DIEN-11-BENZYLIDENE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING DISEASES | BAYER IP GMBH (DE) | 2015-08-19 | — | — | EP | disclosed |
| US-20090082529-A1 | Polyester, Process for Producing Polyester, and Polyester Molded Article | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20080249280-A1 | Process for Producing Polyester, Polyester Produced Using Said Process, and Polyester Molded Product | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2008-10-09 | — | — | US | disclosed |
| CN-101263175-A | Polyester, process for production of polyester, and polyester molded article | TOYO BOSEKI (JP) | 2008-09-10 | — | — | CN | disclosed |
| CN-101208371-A | Method for preparing polyester and polyester manufactured by the method as well as polyester formed body | TOYO BOSEKI (JP) | 2008-06-25 | — | — | CN | disclosed |
| EP-1932867-A1 | POLYESTER, PROCESS FOR PRODUCTION OF POLYESTER, AND POLYESTER MOLDED ARTICLE | Toyo Boseki Kabushiki Kasisha (JP) | 2008-06-18 | — | — | EP | disclosed |
| WO-2008038018-A1 | NOVEL MINOR GROOVE BINDERS | UNIVERSITY OF STRATHCLYDE (GB) | 2008-04-03 | — | — | WO | disclosed |
| EP-1842868-A1 | PROCESS FOR PRODUCING POLYESTER, POLYESTER PRODUCED USING SAID PROCESS, AND POLYESTER MOLDED PRODUCT | Toyo Boseki Kabushiki Kasisha (JP) | 2007-10-10 | — | — | EP | disclosed |
| EP-0638581-B1 | PHOSPHONIC DIESTER DERIVATIVE | OTSUKA PHARMA CO LTD (JP) | 1998-12-23 | — | — | EP | disclosed |
| US-5480874-A | THIAZOLE AND IMIDAZOLE DERIVATIVES; ANTIHYPERLIPIDEMICS AND HYPOGLYCEMICS | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1996-01-02 | — | — | US | disclosed |
| EP-0638581-A1 | PHOSPHONIC DIESTER DERIVATIVE | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1995-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11986471-B2 | Compounds and methods of use | XDH, F12, LPXN | MRGPRX4 62/4885TP53 2141/4885PKM 1652/4885 |
| US-11077101-B1 | Compounds and methods of use | XDH, F12, LPXN | MRGPRX4 62/4885TP53 2141/4885PKM 1652/4885 |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | XDH, F12, LPXN | MRGPRX4 62/4885TP53 2141/4885PKM 1652/4885 |
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | TNF, HLA-DRB1, GSTK1 | MRGPRX4 780/4885TP53 229/4885PKM 3882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.